Five Phase III Data Readouts To Look Out For In Q2
Crunch Time For Alexion, Aldeyra, Byondis, Novan
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
You may also be interested in...
Tuomo Pätsi of US biotech firm Seagen discusses plans for the rollout of Tukysa in Europe, how it successfully used a new mechanism for approval in Great Britain, and why the UK will be a go-to market for future innovative drug filings.
Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.
The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.